Introduction {#s1}
============

Proper balance between inhibitory and excitatory connections is important for proper functioning of neuronal circuits ([@bib28]; [@bib2]). Cell adhesion molecules have a critical role in coordinating the apposition of presynaptic terminals with postsynaptic sites of differentiation ([@bib42]; [@bib44]). While much work has been done to determine the molecular organization of cell adhesion molecules at excitatory synapses, less is known about how these components are organized at inhibitory synapses.

Neuroligins are a family of postsynaptic cell adhesion molecules that interact trans-synaptically with their corresponding presynaptic neurexin binding partners to mediate proper synaptic function ([@bib39]; [@bib6]). Rats express three neuroligins (NLGN1-3): NLGN1 is expressed exclusively at excitatory synapses, NLGN2 is selectively present at inhibitory synapses, while NLGN3 is found at both excitatory and inhibitory synapses ([@bib41]; [@bib4]; [@bib36]). NLGN2 and 3 share many previously identified domains both in their extracellular and intracellular regions. Despite the similarities between the two proteins, it is currently unknown whether they perform the same function at inhibitory synapses. One notable difference between NLGN2 and 3 resides in the extracellular region at splice site A which has previously been proposed to affect NLGN binding to its presynaptic neurexin partner ([@bib20]; [@bib7]).

It has been suggested that NLGN2 functions through a direct interaction on its cytoplasmic tail with gephyrin, a scaffold protein thought to be essential for stabilizing glycine and GABA~A~ receptors at inhibitory synapses ([@bib8]; [@bib40]). In addition, it has been proposed that collybistin, a brain-specific guanine nucleotide exchange factor (GEF), helps regulate the localization of gephyrin, and that NLGN2 is a specific activator of collybistin via a direct interaction at the proline rich region in its cytoplasmic tail ([@bib22]; [@bib31]; [@bib37]). While previous studies have been able to link these interactions to NLGN2, there has been no direct study of whether these interactions are necessary for proper functioning of NLGNs at inhibitory synapses.

To investigate the importance of NLGN2 and 3 at inhibitory synapses, we used microRNAs targeted to NLGN2 or 3 individually. We found that NLGN2 is a critical component of inhibitory synapses while NLGN3 function at inhibitory synapses depends on the presence of NLGN2. Further investigation expressing chimeric constructs of NLGN2 and 3 in isolation, using a microRNA targeting all three endogenously expressed NLGNs 1, 2, and 3, identified a previously uncharacterized domain in the extracellular region that accounted for this functional difference between NLGN2 and 3. Using a similar technique to study the importance of the intracellular region in NLGN function at inhibitory synapses, we found a critical requirement for the cytoplasmic tail and identified two key residues that are separately involved in gephyrin-dependent and gephyrin-independent mechanisms of NLGN function at inhibitory synapses. We further show that an autism-associated mutation inhibits the gephyrin-dependent pathway while a phosphorylation site is responsible for modulating the gephyrin-independent pathway. These findings identify new mechanisms for NLGN function, particularly at inhibitory synapses, and provide new avenues of study for elucidating the molecular mechanisms present at inhibitory synapses.

Results {#s2}
=======

NLGN2 is the critical NLGN at inhibitory synapses {#s2-1}
-------------------------------------------------

To determine the relative contributions of NLGN2 and 3 to inhibitory synaptic transmission, we utilized targeted microRNA constructs to knockdown either NLGN2 or 3 (validated in [Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"} and [@bib34]). We biolistically transfected organotypic hippocampal slices with our constructs of interest and performed dual-whole cell recordings from CA1 neurons 7--10 days after transfection. Compared to a previously validated knockdown construct of NLGNs 1--3 ([@bib33]) which reduces inhibitory synaptic transmission to about 50% ([Figure 1a](#fig1){ref-type="fig"}) we found that while NLGN2 knockdown alone recapitulated the 50% decrease in inhibitory synaptic transmission ([Figure 1b and d](#fig1){ref-type="fig"}), NLGN3 knockdown alone had no effect on inhibitory synaptic transmission ([Figure 1c and d](#fig1){ref-type="fig"}). Furthermore, while overexpression of NLGN3 alone does enhance inhibitory synaptic transmission ([Figure 1e and g](#fig1){ref-type="fig"}), overexpression of NLGN3 with a NLGN2 knockdown construct fails to enhance inhibitory responses ([Figure 1f and g](#fig1){ref-type="fig"}), suggesting that NLGN3 requires the presence of NLGN2 to function at inhibitory synapses. This is consistent with previous results showing no enhancement of inhibitory responses when NLGN3 was overexpressed on a NLGN1-3 knockdown background ([@bib33]). Notably, NLGN3 overexpression on a NLGN2 knockdown background still enhanced excitatory responses similar to NLGN3 overexpression alone ([Figure 1---figure supplement 1b,c and d](#fig1s1){ref-type="fig"}), suggesting our effects are specific for inhibitory synapses.10.7554/eLife.19236.002Figure 1.Neuroligin 2 is the critical neuroligin at inhibitory synapses.(**a**) Knockdown of endogenous neuroligins 1--3 reduces inhibitory responses compared to untransfected control cells (\*p=0.0391, n = 9). (**b**) Scatter plot showing reduction in IPSCs in NLGN2 microRNA-transfected neurons compared to untransfected controls (\*\*\*p=0.0002, n = 15). (**c**) Scatter plot showing no reduction in IPSCs in NLGN3 microRNA-transfected neurons compared to untransfected controls (p=0.3013, n = 12). (**d**) Summary graph of b and c. (**e**) Scatter plot showing overexpression of NLGN3 enhances IPSCs compared to untransfected controls (\*\*p=0.0084, n = 15). (**f**) Scatter plot showing overexpression of NLGN3 combined with NLGN2 knockdown fails to enhance IPSCs (p=0.2661, n = 12). (**g**) Summary graph of e and f. For panels a-c and e-f, open circles are individual pairs, filled circle is mean ± s.e.m. Black sample traces are control, green are transfected. Scale bars represent 100 pA and 50 ms. For panels a, d, and g summary graph plots mean transfected amplitude ± s.e.m, expressed as a percentage of control amplitude. Significance above each column represents pairwise comparison between transfected and untransfected cells. See also [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.19236.002](10.7554/eLife.19236.002)10.7554/eLife.19236.003Figure 1---figure supplement 1.Validation of NLGN2 knockdown construct and EPSCs for NLGN3 overexpression.(**a**) qRT-PCR bar graph shows mean ± s.e.m. of NLGN2 mRNA remaining following NLGN2miR transduction normalized to control GFP transduction (n = 2 technical replicates). (**b**) Scatter plot showing overexpression of NLGN3 enhances EPSCs compared to untransfected controls (\*\*\*p=0.0002, n = 15). (**c**) Scatter plot showing overexpression of NLGN3 combined with NLGN2 knockdown enhances EPSCs (\*\*p=0.0078, n = 9). (**d**) Summary graph of b and c. For panels b and c, open circles are individual pairs, filled circle is mean ± s.e.m. Black sample traces are control, green are transfected. Scale bars represent 100 pA and 50 ms. For panel d, summary graph plots mean transfected amplitude ± s.e.m, expressed as a percentage of control amplitude. Significance above each column represents pairwise comparison between transfected and untransfected cells**DOI:** [http://dx.doi.org/10.7554/eLife.19236.003](10.7554/eLife.19236.003)

Difference between NLGN 2 and 3 function at inhibitory synapses resides in distinct domain in the extracellular region {#s2-2}
----------------------------------------------------------------------------------------------------------------------

To determine where this functional difference between NLGN2 and 3 at inhibitory synapses resides, we made chimeric constructs and expressed them on the reduced endogenous NLGN (NLGN1-3miR) background to study the effects of our constructs in isolation ([Figure 2a](#fig2){ref-type="fig"}). Expression of the full-length NLGN2 resulted in a large enhancement of inhibitory currents ([Figure 2b and e](#fig2){ref-type="fig"}). Expression of a construct containing the NLGN2 extracellular region and NLGN3 cytoplasmic tail enhanced inhibitory currents ([Figure 2c and e](#fig2){ref-type="fig"}) similar to full-length NLGN2 ([Figure 2e](#fig2){ref-type="fig"}). However, expression of a construct containing the NLGN3 extracellular region and NLGN2 intracellular region failed to enhance inhibitory currents ([Figure 2d and e](#fig2){ref-type="fig"}), suggesting that the functional difference between NLGN2 and 3 at inhibitory synapses resides in the extracellular region. Importantly, while the NLGN3 extracellular-NLGN2 intracellular chimeric construct failed to enhance inhibitory responses, it was still able to potentiate excitatory responses ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), indicating that this construct is expressed and functional. It further shows that there are differential requirements for NLGN3 function at inhibitory versus excitatory synapses, and that the NLGN2 c-tail is capable of functioning at excitatory synapses.10.7554/eLife.19236.004Figure 2.Difference between NLGN2 and 3 function at inhibitory synapses resides in the extracellular region.(**a**) To determine where this functional difference between NLGN2 and 3 resides, we made chimeric constructs and expressed them on a reduced endogenous neuroligin background. Black TM is transmembrane domain. (**b**) Scatter plot showing expression of NLGN2 on a NLGN1-3miR knockdown background enhances IPSCs compared to untransfected controls (\*\*\*\*p\<0.0001, n = 25). (**c**) Scatter plot showing expression of a construct containing the NLGN2 extracellular region and NLGN3 cytoplasmic tail (NLGN2e-3ctail) on a NLGN1-3miR knockdown background enhanced IPSCs (\*\*p=0.002, n = 10). (**d**) Scatter plot showing expression of a construct containing the NLGN3 extracellular region and NLGN2 cytoplasmic tail (NLGN3e-2ctail) on a NLGN1-3miR knockdown background failed to enhance IPSCs (p=0.5771, n = 11). (**e**) Summary graph of b-d. Effect of expressing NLGN3e-2ctail is significantly less than expression of NLGN2e-3ctail (\*p=0.0124) or NLGN2 (\*\*p=0.0067). For panels b-d, open circles are individual pairs, filled circle is mean ± s.e.m. Black sample traces are control, green are transfected. Scale bars represent 100 pA and 50 ms. For panel e, graph plots mean transfected amplitude ± s.e.m, expressed as a percentage of control amplitude. Significance above each column represents pairwise comparison between transfected and untransfected cells. See also [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.19236.004](10.7554/eLife.19236.004)10.7554/eLife.19236.005Figure 2---figure supplement 1.Distinct requirements for NLGN function between inhibitory and excitatory synapses.While expression of a construct containing the NLGN3 extracellular region and NLGN2 cytoplasmic tail failed to rescue IPSCs, it was still able to enhance excitatory synaptic transmission (\*\*p=0.0098, n = 10). Open circles are individual pairs, filled circle is mean ± s.e.m. Black sample trace is control, green is transfected. Scale bar represents 100 pA and 50 ms. Summary graph plots transfected amplitude normalized to control ± s.e.m. Significance represents pairwise comparison between transfected and untransfected cells.**DOI:** [http://dx.doi.org/10.7554/eLife.19236.005](10.7554/eLife.19236.005)

We constructed further chimeric constructs to determine where in the extracellular region this difference between NLGN2 and 3 resides and if we could effectively confer NLGN2 function onto NLGN3 by transplanting a critical domain. There are various components located in the extracellular region which have previously been suggested to be important for NLGN function ([Figure 3a](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1a](#fig3s1){ref-type="fig"}). One key component of the extracellular region, the critical dimerization residues, are conserved between NLGN2 and 3, suggesting that differences between NLGN2 and 3 may not be due to differences in ability to dimerize ([@bib11]; [@bib25]; [@bib35]). One notable domain of interest resides in splice site A, which is important for neurexin binding ([@bib20]; [@bib7]). Interestingly, there are many differences between NLGN2 and 3 at this splice site, and these might account for the functional differences between the two.10.7554/eLife.19236.006Figure 3.Identification of critical domain to confer NLGN function at inhibitory synapses.(**a**) Schematic of NLGN2 and 3 showing positions of chimera. Yellow are critical dimerization residues, pink is splice site A, grey SP is signal peptide, and black TM is transmembrane domain. (**b**) Scatter plot showing that adding NLGN2 onto the NLGN3 extracellular region up to the 623rd residue fails to enhance IPSCs (p=0.4229, n = 16). (**c**) Scatter plot showing that adding up to the 180th residue also fails to enhance IPSCs (p=0.2754, n = 10). (**d**) Scatter plot showing that adding up to the 52nd residue is successful at conferring NLGN function at inhibitory synapses and enhancing IPSCs (\*\*p=0.002, n = 10) (**e**) Expression of further chimeric constructs identifies a domain between residue 52--180 on NLGN2 that is sufficient to confer the ability to enhance IPSCs to NLGN3 (\*\*p=0.0039, n = 9). Within this region, we also expressed only (**f**) the region between 52--164 (\*\*p=0.0098, n = 10) or (**g**) residues corresponding to differences in splice site A (164--180) (p=0.0522, n = 12). (**h**) Summary graph. While the chimeric construct NLGN2-52-164-NLGN3 showed enhancement of IPSCs compared to untransfected control cells, the level of potentiation was significantly less than what we see with full-length NLGN2 (\*p=0.0152). For panels b-g, open circles are individual pairs, filled circle is mean ± s.e.m. Black sample traces are control, green are transfected. Scale bars represent 100 pA and 50 ms. For panel h, graph plots mean transfected amplitude ± s.e.m, expressed as a percentage of control amplitude. Significance above each column represents pairwise comparison between transfected and untransfected cells. See also [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.19236.006](10.7554/eLife.19236.006)10.7554/eLife.19236.007Figure 3---figure supplement 1.Chimeric extracellular mutants and effect on excitatory transmission.(**a**) Alignment of the NLGN2 and NLGN3 extracellular regions. Sequence before residue 52 encompasses the highly dissimilar signal sequence and was not included in alignment. Highlighted in magenta is splice site A while key dimerization residues are highlighted in yellow. Relevant sites where chimeric constructs were made are identified in alignment. The first amino acid at the beginning of splice site A at residue 163 is conserved between NLGN2 and 3, therefore our chimera was made after this residue. (**b**) Excitatory responses of chimera that did not potentiate IPSCs. Constructs that did not potentiate IPSCs could still enhance EPSCs including: NLGN3e-2ctail (\*\*p=0.0098, n = 10), NLGN3-623-NLGN2 (\*\*p=0.0039, n = 9), NLGN2-52-164-NLGN3 (\*p=0.0353, n = 14), NLGN2-164-180-NLGN3 (\*\*\*p=0.0005, n = 13). The chimeric construct NLGN3-180-NLGN2 did not enhance EPSCs (p=0.3804, n = 12) and was significantly impaired compared to NLGN3e-2ctail (\*p=0.0111). Summary graph plots transfected amplitude normalized to control ± s.e.m. Significance above each column represents pairwise comparison between transfected and untransfected cells.**DOI:** [http://dx.doi.org/10.7554/eLife.19236.007](10.7554/eLife.19236.007)

Starting from the proximal region closest to the transmembrane region, we progressively added back regions of NLGN2 onto the NLGN3 extracellular region while keeping the NLGN2 c-tail intact. We first inserted a region of NLGN2 up to the 623rd amino acid that contains substantial differences between it and NLGN3 ([Figure 3a](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1a](#fig3s1){ref-type="fig"}). Neither this chimeric construct ([Figure 3b and h](#fig3){ref-type="fig"}) nor one adding back NLGN2 right before splice site A at the 180th amino acid ([Figure 3c and h](#fig3){ref-type="fig"}) was able to enhance inhibitory currents. However, adding back NLGN2 up to the 52nd amino acid was able to potentiate inhibitory currents ([Figure 3d and h](#fig3){ref-type="fig"}). Further refinement showed that transplanting just the domain between the 52nd and 180th amino acid of NLGN2 was able to fully confer NLGN2 ability to potentiate inhibitory currents onto NLGN3 ([Figure 3e and h](#fig3){ref-type="fig"}). Since this domain encompassed the splice site A and a previously uncharacterized domain of the extracellular region, we wanted to know whether the splice site A or the uncharacterized domain alone was sufficient to confer NLGN2 function onto NLGN3. While expression of a chimeric construct containing the uncharacterized extracellular domain of NLGN2 between amino acids 52--164 showed a modest enhancement of inhibitory currents ([Figure 3f and h](#fig3){ref-type="fig"}), it was far less than the effect of the full length NLGN2 ([Figure 3h](#fig3){ref-type="fig"}). A chimera containing only the splice site A domain of NLGN2 ([Figure 3g and h](#fig3){ref-type="fig"}) failed to enhance inhibitory responses. Importantly, all chimeric constructs, except NLGN3-180-NLGN2 which appears non-functional, that failed to potentiate inhibitory responses were still able to potentiate excitatory responses, indicating that they were functional ([Figure 3---figure supplement 1b](#fig3s1){ref-type="fig"}). Together, this suggests that the splice site A domain alone does not account for the differences between NLGN2 and 3 function but that a previously uncharacterized adjacent domain is also required.

A c-tail is required for NLGN function {#s2-3}
--------------------------------------

Since the c-tails of the NLGNs share many similar domains ([Figure 4a](#fig4){ref-type="fig"}), and our previous results showed that the c-tails of NLGN2 and 3 were interchangeable ([Figure 2c and d](#fig2){ref-type="fig"}), we wanted to know whether the c-tail of NLGN1, a NLGN that is selectively present at excitatory synapses, was also capable of functioning at inhibitory synapses. In experiments done on a reduced endogenous NLGN background, full-length NLGN1 was unable to enhance inhibitory responses ([Figure 4b and d](#fig4){ref-type="fig"}), while a chimeric construct containing the NLGN2 extracellular region with a NLGN1 intracellular region was able to enhance inhibitory currents ([Figure 4c and d](#fig4){ref-type="fig"}). To determine whether a c-tail is required at all, we created a truncation mutant lacking most of the c-tail except for a few amino acids closest to the transmembrane domain which might be necessary for proper trafficking of the protein (Δ133, [Figure 4a](#fig4){ref-type="fig"}). While overexpression of this truncation mutant on a wild-type background ([Figure 4---figure supplement 1b and c](#fig4s1){ref-type="fig"}) enhanced inhibitory currents to a similar extent as full-length NLGN2 ([Figure 4---figure supplement 1a and c](#fig4s1){ref-type="fig"}), expression on a reduced endogenous NLGN background showed no potentiation ([Figure 4e and f](#fig4){ref-type="fig"}), indicating that a c-tail is required for proper NLGN function and further underlies the need to observe the effects of our mutant NLGNs on a reduced endogenous background due to the possibility of heterodimerization with endogenous NLGN. Importantly, the effect of the c-tail truncation was not due to impaired surface trafficking as shown by surface immunostaining of the HA-tagged NLGN2 constructs ([Figure 4---figure supplement 1d and e](#fig4s1){ref-type="fig"}).10.7554/eLife.19236.008Figure 4.While NLGN c-tails do not confer specialization to inhibitory synapses, a c-tail is required for NLGN function.(**a**) Alignment of NLGN1-4. Sequences correspond to mouse NLGN1, rat NLGN2, and human NLGN3 and NLGN4. Indicated at residue 133 is where most proximal c-tail truncation was performed. Highlighted in gray is the transmembrane domain. In light red is a conserved residue that is the site of an autism-associated mutation in NLGN4. Highlighted in light purple is the critical region, previously shown to be important for NLGN function at excitatory synapses but not inhibitory synapses ([@bib33]). Highlighted in brown is the gephyrin-binding domain. In green is the proline-rich region, and in light orange is the PDZ domain. Phosphorylation sites are highlighted in yellow. (**b**) Scatter plot showing expression of full-length NLGN1 on a NLGN1-3miR knockdown background failed to enhance inhibitory responses (p=0.6726, n = 19), (**c**) Scatter plot showing expression of a chimeric NLGN2 extracellular region with NLGN1 c-tail on a NLGN1-3miR knockdown background is able to enhance inhibitory responses (\*p=0.0244, n = 11). (**d**) Summary graph. Effect of expressing NLGN2e-1ctail is significantly greater than with full-length NLGN1 (\*p=0.0314). (**e**) Scatter plot showing expression of the c-tail truncation mutant NLGN2Δ133 on a reduced endogenous neuroligin background is unable to enhance inhibitory synaptic responses, indicating that a c-tail is required for NLGN function (p=0.6387, n = 15). (**f**) Summary graph of e. Effect of expressing NLGN2Δ133 is significantly less than with full-length NLGN2 (\*\*\*p=0.0002). For panels b-c and e, open circles are individual pairs, filled circle is mean ± s.e.m. Black sample traces are control, green are transfected. Scale bars represent 100 pA and 50 ms. For panels d and f, graph plots transfected amplitude normalized to control ± s.e.m. Significance above each column represents pairwise comparison between transfected and untransfected cells. See also [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.19236.008](10.7554/eLife.19236.008)10.7554/eLife.19236.009Figure 4---figure supplement 1.Further characterization of c-tail deletion mutant.(**a-b**) Scatter plots showing overexpression on a wild-type background of (**a**) NLGN2 (\*\*p=0.0039, n = 9) and (**b**) NLGN2Δ133 (\*p=0.042, n = 11), both potentiate inhibitory responses. (**c**) Summary of a-b. (**d**) Immunostaining of dissociated hippocampal cultures transfected with NLGNmiRs-GFP alone or with either HA-tagged NLGN2 or HA-tagged NLGN2Δ133 and surface stained for HA. Scale bar represents 20 μm. (**e**) Summary of d. Graph plots intensity of HA signal normalized to GFP (p=0.189, n = 11 cells per group). Error bars are mean ± s.e.m. For panels a and b, open circles are individual pairs, filled circle is mean ± s.e.m. Black sample traces are control, green are transfected. Scale bars represent 100 pA and 50 ms. For panel c, graph plots transfected amplitude normalized to control ± s.e.m. Significance above each column represents pairwise comparison between transfected and untransfected cells.**DOI:** [http://dx.doi.org/10.7554/eLife.19236.009](10.7554/eLife.19236.009)

Previously identified domains not critical for NLGN function at inhibitory synapses {#s2-4}
-----------------------------------------------------------------------------------

To determine what domain(s) in the c-tail are necessary for NLGN function at inhibitory synapses, we made a series of truncations to the c-tail of NLGN2, deleting previously identified domains proposed to be important for its function (full diagram of relevant sites in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). First, it has previously been suggested that PSD-95 binds NLGN2, since it contains a PDZ domain ([@bib21]). Second, in addition to PSD-95, which is localized to excitatory synapses, S-SCAM is another protein that is localized to both excitatory and inhibitory synapses and can also interact via the NLGN2 PDZ domain ([@bib43]). To determine whether any of these interactions via the PDZ domain are important for NLGN2 function, we made a truncation mutant lacking the entire PDZ domain (NLGN2Δ4). We found that deleting the PDZ domain did not alter the function of NLGN2 ([Figure 5a and d](#fig5){ref-type="fig"}). Proximal to the PDZ domain is the proline-rich region, which has been shown to be important for collybistin binding and enabling the recruitment of gephyrin ([@bib22]; [@bib31]; [@bib37]). However, excision of this domain (NLGN2Δ32--39) or truncation of this domain and everything downstream of it including the PDZ domain (NLGN2Δ39) still resulted in significant potentiation of inhibitory currents ([Figure 5b and d](#fig5){ref-type="fig"}).10.7554/eLife.19236.010Figure 5.Previously identified domains not required for NLGN2 function.(**a--c**) Scatter plots showing replacement of endogenous neuroligin with truncation mutants (**a**) lacking the PDZ domain (NLGN2Δ4) (\*\*p=0.0098, n = 11), (**b**) truncation of all regions downstream of the proline rich region (NLGN2Δ39) (\*\*p=0.0017, n = 14), or (**c**) truncation of all regions downstream of the gephyrin binding domain (NLGN2Δ69) (\*\*p=0.0017, n = 18), is still able to potentiate inhibitory synaptic responses compared to paired neighboring control cells. (**d**) Summary graph. Shown are further mutants including deletion of only the proline rich region (NLGN2Δ32--39) (\*\*p=0.002, n = 10), deletion of only the gephyrin binding domain (NLGN2Δ55--69) (\*p=0.0273, n = 10) or expression of a phospho-mimic point mutant that has been shown to disrupt gephyrin binding (NLGN2 Y770A) (\*\*\*p=0.0005, n = 17), which all still potentiate inhibitory responses. For panels a-c, open circles are individual pairs, filled circle is mean ± s.e.m. Black sample traces are control, green are transfected. Scale bars represent 100 pA and 50 ms. For panel d, graph plots transfected amplitude normalized to control ± s.e.m. Significance above each column represents pairwise comparison between transfected and untransfected cells. See also [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.19236.010](10.7554/eLife.19236.010)10.7554/eLife.19236.011Figure 5---figure supplement 1.More detailed NLGN alignment showing where all truncations and point mutations were made.Highlighted in gray is the transmembrane domain. In light red is a conserved residue that is a site of an autism-associated mutation in NLGN4. Highlighted in light purple is the critical region, previously shown to be important for NLGN function at excitatory synapses but not inhibitory synapses ([@bib33]). Highlighted in brown is the gephyrin-binding domain. In green is the proline-rich region, and in light orange is the PDZ domain. Phosphorylation sites are highlighted in yellow.**DOI:** [http://dx.doi.org/10.7554/eLife.19236.011](10.7554/eLife.19236.011)

Another key domain suggested to be critical for NLGN function is the gephyrin-binding domain ([@bib31]). The reigning model of NLGN function at inhibitory synapses purports that the interaction of gephyrin with NLGN2 via its gephyrin-binding domain enables the recruitment of GABA~A~ receptors to the synapse ([@bib8]; [@bib40]). However, there have also been reports of gephyrin-independent mechanisms of GABA~A~ receptor enrichment at inhibitory synapses ([@bib27]; [@bib23]). To determine whether the gephyrin-binding domain is critical for NLGN2 function, we employed a variety of methods to either disrupt or excise this region of interest. Surprisingly, we found that expression of NLGN2 with a phospho-mimic mutation previously shown to disrupt gephyrin binding (NLGN2 Y770A) ([@bib31]; [@bib17]), excision of the whole gephyrin-binding domain (NLGN2Δ55--69), or, most dramatically, truncation of the gephyrin-binding domain and everything downstream of it, including all known functional domains of the NLGN2 c-tail (NLGN2Δ69), all still displayed significant potentiation of inhibitory currents ([Figure 5c and d](#fig5){ref-type="fig"}).

While our results suggest that the gephyrin-binding domain is not critical for NLGN2 function, we wondered whether gephyrin, itself, is required. To address this, we created a targeted knockdown construct for gephyrin that effectively knocks down more than 90% of gephyrin expression ([Figure 6---figure supplement 1a and b](#fig6s1){ref-type="fig"}). Expression of this construct reduced inhibitory currents to about 50%, similar to knockdown of all endogenous NLGNs ([Figure 6a and c](#fig6){ref-type="fig"}). Surprisingly, a NLGN2 truncation mutant lacking all known functional domains of the c-tail (NLGN2Δ69) coexpressed with our gephyrin and endogenous NLGN knockdown constructs was fully capable of enhancing inhibitory currents ([Figure 6b and c](#fig6){ref-type="fig"}). These results indicate that NLGN2 can function, not only without previously known domains, but entirely independently of gephyrin as well.10.7554/eLife.19236.012Figure 6.Gephyrin-independent NLGN2 function.(**a**) Scatter plot showing overexpression of a Gephyrin-miR construct to knockdown gephyrin expression significantly reduces inhibitory synaptic responses (\#p=0.0156, n = 8). (**b**) Scatter plot showing replacement of endogenous neuroligin with a truncation mutant lacking all known domains of neuroligin 2 (NLGN2Δ69) on a gephyrin knockdown background is still able to potentiate inhibitory synaptic responses, indicating that neuroligin 2 is able to function independently of gephyrin (\*\*p=0.0039, n = 9). (**c**) Summary graph. Asterisks indicate significant enhancement compared to control cells where \*\*p\<0.01 and \*\*\*p\<0.001, while hash sign indicates significant depression compared to control cells where \#p\<0.05. For panels a and b, open circles are individual pairs, filled circle is mean ± s.e.m. Black sample traces are control, green are transfected. Scale bars represent 100 pA and 50 ms. For panel c, graph plots transfected amplitude normalized to control ± s.e.m. Significance above each column represents pairwise comparison between transfected and untransfected cells. See also [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.19236.012](10.7554/eLife.19236.012)10.7554/eLife.19236.013Figure 6---figure supplement 1.Characterization of Gephyrin knockdown construct.(**a**) Graph shows mean ± s.e.m. of gephyrin mRNA remaining following Gephyrin-miR transduction normalized to control (n = 3 technical replicates). (**b**) Western blot of lysates taken from dissociated hippocampal cultures following Gephyrin-miR transduction compared to control uninfected neurons. Shown is representative image of 6 technical replicates. Top band is gephyrin, lower band is actin. Size in kDa.**DOI:** [http://dx.doi.org/10.7554/eLife.19236.013](10.7554/eLife.19236.013)

NLGN function at inhibitory synapses requires two distinct regions in the c-tail {#s2-5}
--------------------------------------------------------------------------------

Our results suggested that there might be a previously uncharacterized region of the NLGN c-tail that is critical for its function at inhibitory synapses. We made further truncations starting at the region closest to our most terminal c-tail truncation (NLGN2Δ133) and found that deletion of a 35 amino acid stretch from that point (NLGN2Δ98--133) resulted in the loss of enhancement of inhibitory responses ([Figure 7a and e](#fig7){ref-type="fig"}). Further refinement identified a domain of 16 amino acids that, when deleted (NLGN2Δ117--133), also showed no enhancement ([Figure 7b and e](#fig7){ref-type="fig"}).10.7554/eLife.19236.014Figure 7.Identification of critical residues in NLGN2 c-tail.(**a**) Scatter plot showing deletion of a region from the most proximal c-tail truncation (NLGN2Δ98--133) failed to enhance inhibitory responses (p=0.1698, n = 17). (**b**) Further refining this area of interest, NLGN2Δ117--133 still failed to enhance inhibitory responses (p=0.6953, n = 10). (**c**) Scatter plot showing double point mutant with autism-associated mutation at R705 and phospho-null mutation at S714 (NLGN2-R705C-S714A) also showed deficits in inhibitory transmission (p=0.0522, n = 12). (**d**) Scatter plot showing double point mutant with autism-associated mutation at R705 and phospho-mimic mutation at S714 (NLGN2-R705C-S714D) displayed normal enhancement of IPSCs (\*\*\*p=0.0002, n = 15). (**e**) Summary graph. Expression of full-length NLGN2 results in greater enhancement of IPSCs compared to NLGN2Δ98--133 (\*\*\*p=0.0001), NLGN2Δ117--133 (\*\*\*\*p\<0.0001), and NLGN2-R705C-S714A (\*\*p=0.0061). Expression of NLGN2-R705C-S714D results in greater enhancement of IPSCs compared to NLGN2-R705C-S714A (\*p = 0.0429). (**f**) Scatter plot showing double point mutant with autism-associated mutation at R705 and a phospho-mimic point mutant shown to disrupt gephyrin binding at Y770 is still able to enhance inhibitory responses (\*\*\*p=0.0005, n = 17). (**g**) Scatter plot showing double point mutant with phospho-null mutation at S714 and a phospho-mimic point mutant shown to disrupt gephyrin binding at Y770 exhibited modest enhancement of IPSCs (\*p=0.0274, n = 13). (**h**) Summary graph. While the double mutant NLGN2-S714A-Y770A showed enhancement of IPSCs compared to untransfected control cells, the level of potentiation was far less than what we see with full-length NLGN2 (\*\*p=0.0089). For panels a-d, and f-g open circles are individual pairs, filled circle is mean ± s.e.m. Black sample traces are control, green are transfected. Scale bars represent 100 pA and 50 ms. For panel e and h, bar graph plots transfected amplitude normalized to control ± s.e.m. Significance above each column represents pairwise comparison between transfected and untransfected cells. See also [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.19236.014](10.7554/eLife.19236.014)10.7554/eLife.19236.015Figure 7---figure supplement 1.Individual c-tail point mutations do not affect NLGN2 function.(**a--c**) Scatter plots showing replacement of endogenous neuroligin with individual mutants of either (**a**) phospho-null mutation (\*p=0.0195, n = 9), (**b**) phospho-mimic mutation (\*\*\*p=0.0007, n = 13), or (**c**) autism-associated mutation (\*p=0.0391, n = 9) still potentiates IPSCs. (**d**) Summary graph. For panels a-c, open circles are individual pairs, filled circle is mean ± s.e.m. Black sample traces are control, green are transfected. Scale bars represent 100 pA and 50 ms. For panel d, bar graph plots transfected amplitude normalized to control ± s.e.m. Significance above each column represents pairwise comparison between transfected and untransfected cells.**DOI:** [http://dx.doi.org/10.7554/eLife.19236.015](10.7554/eLife.19236.015)

We next sought to identify any candidate residues that could be important within this domain. We were informed by our previous results that any NLGN c-tail would be able to function at inhibitory synapses and thus looked for residues that were shared among all the NLGNs. We focused on two sites, a residue at R705 linked to an autism mutation previously found in NLGN4 that inhibited its function at excitatory synapses ([@bib3]), and a putative phosphorylation site at S714 previously shown to affect gephyrin binding to NLGN2 ([@bib1]).

Individual mutations at these sites, either by expressing the phospho-null (NLGN2-S714A) ([Figure 7---figure supplement 1a and d](#fig7s1){ref-type="fig"}), phospho-mimic (NLGN2-S714D) ([Figure 7---figure supplement 1b and d](#fig7s1){ref-type="fig"}), or the analogous autism point mutation (NLGN2-R705C) ([Figure 7---figure supplement 1c and d](#fig7s1){ref-type="fig"}), still enhanced inhibitory responses comparable to full-length NLGN2. However, when we expressed the double point mutant of the autism-associated mutation with the phospho-null mutation (NLGN2-R705C-S714A) ([Figure 7c and e](#fig7){ref-type="fig"}) the enhancement was dramatically reduced, suggesting that together these residues are critical for NLGN function at inhibitory synapses. Notably, when we tested another double point mutant with a phospho-mimic mutation at S714 instead, (NLGN2-R705C-S714D) ([Figure 7d and e](#fig7){ref-type="fig"}), we still saw robust enhancement of inhibitory currents, showing that our effect is phosphorylation-dependent.

Gephyrin-dependent and gephyrin-independent mechanisms {#s2-6}
------------------------------------------------------

Our finding that there are two distinct requirements in the c-tail for NLGN function at inhibitory synapses could explain why we were unable to see an effect earlier with our gephyrin mutants if there are both gephyrin-dependent and gephyrin-independent mechanisms for NLGN function at inhibitory synapses. To determine whether this was the case, we made two more double mutants, combining either the autism mutation or phospho-null mutation with the point mutation in the gephyrin-binding domain that inhibits gephyrin binding (NLGN2-R705C-Y770A or NLGN2-S714A-Y770A). Since the Y770A mutation inherently blocks the gephyrin-dependent pathway, we wanted to know which of our mutations when combined with this manipulation would reveal the presence of a gephyrin-independent pathway. We expect that if either the R705C or S714A point mutations were in a gephyrin-independent pathway, we would observe reduced enhancement of inhibitory currents when combined with the Y770A point mutation that blocks gephyrin binding.

The combined autism mutation and gephyrin-binding double point mutant (NLGN2-R705C-Y770A) exhibited enhancement comparable to full-length NLGN2 ([Figure 7f and h](#fig7){ref-type="fig"}), while the combined phospho-null mutation and gephyrin-binding double point mutant (NLGN2-S714A-Y770A) showed significantly reduced enhancement ([Figure 7g and h](#fig7){ref-type="fig"}). Thus, while the three individual point mutations on their own still exhibited enhancement of inhibitory currents, it was only when we mutated both S714 and R705 or S714 and Y770A did we see impairment, suggesting these mutations to be involved in separate pathways. Also, mutation of both R705 and Y770 still exhibited enhancement of inhibitory currents similar to full-length NLGN2, suggesting that they function in the same pathway. Together, we propose the existence of two pathways: a gephyrin-independent pathway modulated at S714 and a gephyrin-dependent pathway modulated at both R705 and Y770 ([Figure 8](#fig8){ref-type="fig"}).10.7554/eLife.19236.016Figure 8.Separate gephyrin-dependent and gephyrin-independent mechanisms for neuroligin function at inhibitory synapses.We propose separate gephyrin-dependent and gephyrin-independent mechanisms for NLGN function at inhibitory synapses. In our NLGN2-R705C-S714A manipulation, we block the gephyrin-independent pathway by preventing phosphorylation at the S714 residue, and also block the gephyrin-dependent pathway by the autism-associated mutation at R705. Therefore, the resulting effect we see is impaired function at inhibitory synapses. In our NLGN2-R705C-S714D manipulation, we facilitate the gephyrin-independent pathway by mimicking phosphorylation at the S714 residue, while the gephyrin-dependent pathway is blocked by the autism-associated mutation at R705. The resulting effect we see is intact function at inhibitory synapses. In our NLGN2-R705C-Y770A manipulation, we only block the gephyrin-dependent pathway with the autism-associated mutation at R705 and a mutation at Y770 that blocks gephyrin-binding. The resulting effect we see is intact function at inhibitory synapses. In our NLGN2-S714A-Y770A manipulation, we block the gephyrin-independent pathway by preventing phosphorylation at the S714 residue, and also block the gephyrin-dependent pathway with the mutation at Y770 that blocks gephyrin-binding. Therefore, the resulting effect we see is impaired function at inhibitory synapses. Green is gephyrin. Yellow residues are phosphorylation sites. The Y770A point mutant has been previously characterized and shown to function as a phospho-mimic mutation that blocks gephyrin binding ([@bib17]).**DOI:** [http://dx.doi.org/10.7554/eLife.19236.016](10.7554/eLife.19236.016)

Discussion {#s3}
==========

Our results have uncovered the critical features of NLGN2 for proper inhibitory synaptic function and reveal domains in both the extracellular and intracellular regions of the NLGNs that are necessary for their function specifically at inhibitory synapses. Our systematic dissection of the relative contributions of NLGN2 and 3 to inhibitory synaptic function through targeted knockdown of one or the other revealed that while NLGN3 appears to be a dispensable component, NLGN2 is not and that, in fact, NLGN3 function depends on the presence of NLGN2. Further analysis via expression of chimeric NLGN2/3 constructs on a reduced endogenous NLGN background revealed that this difference between NLGN2 and 3 function at inhibitory synapses is due to differences within a domain in the extracellular region corresponding to a site important for neurexin binding, as well as a proximal uncharacterized region.

While this result seemed to suggest that the intracellular region is not important, our results clearly show that, although the intracellular region of any NLGN is sufficient for function at inhibitory synapses, if paired with the extracellular region of NLGN2, a c-tail is very much required. Thus, a NLGN2 truncation lacking most of the intracellular region failed to enhance inhibitory responses while maintaining a normal ability to traffic to the surface. Further refinement identified two distinct regions of the NLGN c-tail corresponding to gephyrin-dependent and gephyrin-independent mechanisms that enable proper function at inhibitory synapses. These results suggest that while the extracellular region is important for specifying function at an inhibitory or excitatory synapse, the intracellular region is critical for carrying out that function at both an inhibitory or excitatory synapse.

Due to the heterogeneous nature of inhibitory synapses, one question that arises is whether our observations are relevant only for particular subsets of inhibitory synapses. Previous work using simultaneous recording from connected neurons showed that NLGN2 knockout animals specifically displayed a deficit in PV but not SOM inputs onto hippocampal pyramidal neurons ([@bib18]). A similar set of studies in NLGN3 knockout animals showed an enhancement of CCK inputs but no change in PV inputs ([@bib16]). In our experimental system, we find that while knockdown of NLGN2 critically affects inhibitory transmission, knockdown of NLGN3 does not. Our results are consistent with the observations at PV synapses, suggesting either that our stimulation placement preferentially recruits responses from these types of synapses or that in our system PV inputs are responsible for a large proportion of inhibitory responses.

One limitation of our study is that the results we observe may not occur universally among all brain regions. Indeed, recent work has shown that within the cerebellum the basket/stellate cell synapses onto Purkinje cells exhibit a decrease in mIPSC frequency but not amplitude with knock-out of just NLGN2 while the double knockout of NLGN2 and 3 exhibit a much more dramatic impairment in both mIPSC frequency and amplitude ([@bib45]). In addition, there are inherent limitations with the organotypic slice preparation we have utilized in our experiments including but not limited to the presence of sprouting and rewiring of circuits and the high level of expression imparted by biolistic transfection.

The role of NLGN3 at inhibitory synapses {#s3-1}
----------------------------------------

What might be the role of NLGN3 at inhibitory synapses since our results show that its absence does not affect inhibitory transmission, and that NLGN3 requires the presence of NLGN2 to function at inhibitory synapses? One possible explanation is that NLGN3 functions as an available mechanism to quickly enhance existing inhibitory synapses. Previous work looking at overexpression of NLGN2 or 3 in cerebral cortical neurons noticed that the majority of NLGN3 was not localized synaptically while the majority of NLGN2 was synaptically located ([@bib13]). From this, we can surmise the presence of a readily available pool of NLGN3 located outside the synapse that could be recruited and associate with NLGN2 in response to induction of plasticity.

This hypothesis is further strengthened by our result showing that transplanting a domain of the NLGN2 extracellular region corresponding to a key area associated with neurexin binding fully enabled NLGN3 to function at inhibitory synapses by itself. It suggests that NLGN3 is unable to bind to the corresponding neurexin partner at inhibitory synapses alone and that it needs to heterodimerize with NLGN2 in order to function. Previous work has already shown that different neurexin isoforms are expressed at different types of synapses, and that the neurexin isoform expressed at inhibitory synapses can bind to NLGN2 but not NLGN1 ([@bib14]; [@bib15]). Thus, it is possible that NLGN3, which seems to be able to bind to the neurexins at excitatory synapses by itself, needs to associate with NLGN2 in order to bind to the neurexins at an inhibitory synapse, and this special property of NLGN2 resides in a unique domain in its extracellular region that we have now identified. An alternative hypothesis, and one that does not necessarily require the presence of NLGN2/3 heteromers, is that there is another molecule in addition to neurexin that interacts within that domain of NLGN2 to stabilize the synapse and enable recruitment of NLGN3.

Extracellular region confers specificity {#s3-2}
----------------------------------------

Our results showing that a chimeric NLGN3 extracellular region with a NLGN2 intracellular region was unable to potentiate inhibitory responses but could still enhance excitatory responses indicates that there are differential requirements for NLGN function at excitatory versus inhibitory synapses and that the extracellular region is critical for mediating this specificity. This is not surprising given that neurexin binding occurs at the extracellular region and that different neurexin isoforms are present preferentially at particular synapses. However, there could be other possible interactors that help define this functional specificity. Previous work has shown that NMDA receptors are able to bind to the extracellular region of NLGN1 but not NLGN2 or 3 ([@bib5]). In addition, the presence of the B splice site insertion in NLGN1 enables it to enhance NMDA currents and promote LTP, and this site is notably absent in NLGN3 ([@bib34]). For inhibitory synapses, previous work has shown that MAM domain-containing glycosylphosphatidylinositol anchor proteins (MDGAs) are able to negatively regulate the function of NLGN2 through an interaction within their extracellular region ([@bib30]; [@bib26]). Also, there are multiple glycosylation sites in the extracellular region of the NLGNs and previous work has shown that glycosylation state can affect neurexin binding ([@bib9]; [@bib19]). However, the analogous glycosylation sites initially found in NLGN1 are conserved among both NLGN2 and 3 within our critical domain, suggesting that they may not explain the difference we see in function. Previously identified cysteine residues that form disulfide bonds within the extracellular region are also conserved between NLGN2 and 3 within our critical domain ([@bib19]). Thus, it would be of interest to determine what molecular interactions are occurring at our critical extracellular domain to mediate NLGN function at inhibitory synapses both in baseline conditions and in response to plasticity.

Intracellular region contains the toolbox for NLGN function at both excitatory and inhibitory synapses {#s3-3}
------------------------------------------------------------------------------------------------------

Our results with chimeric constructs show that any NLGN c-tail is able to function at inhibitory synapses if linked with a NLGN2 extracellular region, and that the NLGN2 c-tail is able to function at excitatory synapses when linked with the NLGN3 extracellular region. This suggests that there is no specificity within the c-tail itself to determine NLGN function at either an excitatory or inhibitory synapse. These results are consistent with previous work showing that overexpression on a wild-type background of chimeric constructs containing NLGN1 extracellular linked to NLGN2 intracellular, or NLGN2 extracellular linked to NLGN1 intracellular, is fully capable of enhancing excitatory and inhibitory currents respectively ([@bib15]). Our work eliminates the possibility that previous observations might be due to heterodimerization of chimeric constructs with endogenous NLGNs by expressing all of our chimera on a reduced endogenous NLGN background.

While the c-tail is the toolbox that contains all the functional residues necessary to perform at either an excitatory or inhibitory synapse, it is important to note that the particular type of synapse determines which residues will be utilized. Indeed, prior work has shown that phosphorylation at the gephyrin binding domain enables preferential recruitment of PSD-95 versus gephyrin to the intracellular region of NLGN1 ([@bib17]). In addition, while it has been shown that there is a critical residue in the NLGN3 c-tail that is important for its function at excitatory synapses, mutation of the analogous residue in NLGN2 does not affect its function at inhibitory synapses ([@bib33]). Therefore, the mechanisms we describe are specific for NLGN function at inhibitory synapses.

Gephyrin-dependent and gephyrin-independent mechanisms for NLGN function at inhibitory synapses {#s3-4}
-----------------------------------------------------------------------------------------------

We were surprised to find that not only the PDZ and collybistin domain are dispensable for NLGN function at inhibitory synapses but also the gephyrin-binding domain as well. There have been previous reports of gephyrin-independent function at inhibitory synapses, either in development or during plasticity ([@bib10]; [@bib29]). In addition, previous work done in mice lacking the cytoplasmic protein dystrophin showed selective reduction in clustering of α2 containing GABA~A~ receptors but no change in gephyrin clustering, suggesting there might be dystrophin-dependent and gephyrin-independent mechanisms for clustering of specific GABA~A~ receptor subtypes ([@bib24]). Thus, it would be of interest to determine whether phosphorylation of the S714 site affects dystrophin function.

Phosphorylation at the S714 residue of NLGN2 has been found to negatively regulate the interaction between NLGN2 and gephyrin ([@bib1]). However, our results indicate that phosphorylation at this site positively regulates NLGN2 function through a gephyrin-independent mechanism, since only the phospho-null form is able to block enhancement of inhibitory currents when paired with a mutation that blocks the gephyrin-dependent pathway ([Figure 8](#fig8){ref-type="fig"}). This discrepancy might be explained by the previous study's use of non-neuronal cells for characterization of the interaction between gephryin and the phosphorylation state at that site. It remains to be determined what kinase phosphorylates this particular site and what molecules are recruited in response to phosphorylation to mediate gephyrin-independent NLGN2 function.

The R705C point mutation is the only autism-associated mutation in the NLGNs identified to date that resides in the intracellular region. Previous characterization of this autism mutation at the analogous residue in NLGN3 showed no effect at inhibitory synapses ([@bib12]). This is consistent with our results showing that NLGN2 with the R705C point mutation alone is fully capable of enhancing inhibitory transmission ([Figure 7---figure supplement 1c and d](#fig7s1){ref-type="fig"}). However, by combining the R705C mutation with the S714A mutation, we were able to uncover a deficit in NLGN function ([Figure 8](#fig8){ref-type="fig"}). Similarly, it was only by combining the Y770A mutation with the S714A mutation, not the R705C mutation, that we were able to prevent NLGN2 from enhancing inhibitory currents, suggesting that the R705C mutation operates via a gephyrin-dependent pathway ([Figure 8](#fig8){ref-type="fig"}). These results underscore the additive effects of multiple point mutations, and highlight how disease phenotypes can be due to the interaction of a number of different factors. While the R705C mutation was shown to inhibit PKC-mediated interaction with NLGN4X at excitatory synapses, there is no analogous PKC phosphorylation site in NLGN2 ([@bib3]). Thus, it remains to be determined what molecules interact at this site and how this autism-associated mutation results in disruption of gephyrin binding to NLGN2.

Our findings have highlighted the separate roles of the NLGN extracellular and intracellular regions. The extracellular region is important for specifying function at a particular synapse while the intracellular region is important for carrying out the molecular mechanisms at either an excitatory or inhibitory synapse. We identify a domain in the extracellular region that is necessary and sufficient for specifying NLGN function at inhibitory synapses and elucidate both a gephyrin-dependent and gephyrin-independent mechanism for NLGN function at inhibitory synapses operating via intracellular interactions modulated by a phosphorylation site and an autism-associated mutation. These results advance our fundamental understanding of NLGN function at inhibitory synapses and provide multiple new avenues of study for further dissection of the various molecular interactors of the NLGNs, both extracellularly and intracellularly, and in normal and disease conditions.

Materials and methods {#s4}
=====================

Experimental constructs {#s4-1}
-----------------------

Neuroligin overexpression constructs have previously been described ([@bib33]) and were based on RNAi-proofed HA-tagged rat NLGN2 and human NLGN3. We used an RNAi-proof NLGN1 isoform containing the B splice site. All neuroligin constructs were cloned into the pCAGGS expression plasmid by either PCR for truncations or overlap extension PCR for chimera, deletions, and point mutations followed by In-Fusion cloning (Takara Bio, Japan). All NLGN2 constructs contained an HA-tag and all chimera retained the NLGN2 version of the transmembrane domain. The triple microRNA construct to knockdown neuroligins 1, 2, and 3 (NLGN1-3miR) and NLGN3miR have been previously characterized ([@bib34]; [@bib33]). Targeting sequence for the NLGN2miR construct was TTGCTGTTGAACTTGCTCCAT. Gephyrin-miR targeting sequence was AACAGGGAATGAGCTACTAAA. All targeting sequences were cloned using BLOCK-iT miR RNAi kit (Invitrogen, Waltham, MA). All constructs used for biolistic transfection and lentiviral production co-expressed either a GFP or mCherry fluorophore for visualization.

Lentivirus production {#s4-2}
---------------------

HEK293T cells were co-transfected with psPAX2, pVSV-G, and either NL2miR or Gephyrin-miR using FuGENE HD (Promega, Madison, WI). Supernatant was collected 40 hr later, filtered, and concentrated using PEG-it Virus Precipitation Solution (System Biosciences, Palo Alto, CA). Resulting pellet was resuspended in Opti-mem, flash-frozen, and stored at --80°C.

qRT-PCR {#s4-3}
-------

Primary rat hippocampal dissociated neurons were prepared at E18.5 and infected with lentivirus expressing a Gephyrin-miR, NLGN2miR, or control GFP construct at DIV 4--7. Neurons were harvested at DIV17-18 by lysis and reverse transcribed to synthesize cDNA using a Power SYBR Green Cells-to-CT kit (Life Technologies, Waltham, MA). Amplification of cDNA by real-time PCR was quantified using SYBR Green with the following sequence specific primers: Neuroligin 2, forward-CATTCAGAAGGGCTGTTCCA, reverse- GTCTTCCCGGGAGCTAGTAG; Gephryin, forward- GGGAATGAGCTACTAAATCCTG, reverse- TGATACCCTCATTCAAGGCA.

Immunoblotting {#s4-4}
--------------

Primary rat hippocampal dissociated neurons were prepared at E18.5 and infected with lentivirus expressing Gephyrin-miR construct at DIV 4--7. Neurons were harvested at DIV17-18 in Tris-buffered saline (25 mM Tris pH 7.4, 150 mM NaCl) plus 0.5% Triton-X and protease inhibitor mix (Roche Applied Sciences, cOmplete Protease Inhibitor Cocktail Tablets, Germany). After incubation at 4°C for 30 min, cell lysates were centrifuged for 15 min at 12000 g. Proteins were resolved by SDS-PAGE and analyzed by western blot using antibodies against gephyrin (1:5000, Synaptic Systems, Germany) and actin (1:5000, Millipore C4, Billerica, MA).

Immunostaining and Imaging {#s4-5}
--------------------------

Primary rat hippocampal dissociated neurons were prepared at E18.5 and transfected using Lipofectamine 2000 with pCaggs NLmiRs-GFP and either pCaggs-NLGN2 or pCaggs-NLGN2Δ133. 7 days later cells were prepped for immunostaining for surface and intracellular markers. Cells were first washed with cold HEPES external buffer (115 mM NaCl, 3.5 mM KCl, 10 mM HEPES, 20 mM Glucose, 1 mM MgCl~2~, 1.5 mM CaCl~2~, adjusted to pH 7.3 with NaOH) then incubated with anti-HA antibody (Y-11, 1:250, Santa Cruz Biotech) for 20 mins in the cold. Cells were then washed with HEPES external buffer and fixed in 4% paraformaldehyde in 4% PBS for 15 min room temperature. Cells were then washed with PBS and blocked in 10% goat serum in PBS with 0.1% Triton X-100. Cells were then washed with PBS with 0.1% Triton X-100 and labeled with Alexa 546- conjugated anti-rabbit secondary antibody (1:250, Thermo-Fisher Scientific, Waltham, MA) in PBS with 0.1% Triton X-100 with 2.5% goat serum and mounted with SlowFade Gold Antifade Mountant (Molecular Probes, Waltham, MA). Neurons were imaged with a 100x objective on a Zeiss LSM 510 confocal microscope. For analysis, images were collected and quantified by normalizing the fluorescence intensity of surface-expressed NLGN2 (or NLGN2Δ133) with the fluorescence intensity of GFP in each cell using ImageJ (NIH, Bethesda, MD). All data analysis was done blinded to experimental conditions.

Slice culture and biolistic transfection {#s4-6}
----------------------------------------

Rat slice cultures were prepared on P6--8 as previously described ([@bib38]). All experiments were performed in accordance with established protocols approved by the University of California San Francisco Institutional Animal Care and Use Committee.

Sparse biolistic transfections of organotypic slice cultures were performed 1 day after culturing as previously described ([@bib32]). Briefly, 100 μg total of mixed plasmid DNA was coated on 1 μm-diameter gold particles in 0.5 mM spermidine, precipitated with 0.1 mM CaCl~2~, and washed four times in pure ethanol. The gold particles were coated onto PVC tubing, dried using ultra-pure N~2~ gas, and stored at 4°C in desiccant. DNA-coated gold particles were delivered with a Helios Gene Gun (BioRad, Hercules, CA). When biolistically expressing two plasmids, gold particles were coated with equal amounts of each plasmid and plasmids always expressed different fluorescent markers. Observed frequency of coexpression was nearly 100%. Slices were maintained at 34°C with media changes every other day.

Electrophysiological recording {#s4-7}
------------------------------

Recordings were performed at 7--10 DIV after 6--9 days of expression. Dual whole-cell recordings of CA1 pyramidal neurons were done by simultaneously recording responses from a fluorescent transfected neuron and a neighboring untransfected control neuron. Synaptic responses were evoked by stimulating with a monopolar glass electrode filled with aCSF in stratum radiatum of CA1. Typically each pair of neurons is from a separate slice, whereas on rare occasions two pairs may come from one slice. For all paired recordings, the number of experiments (*n*) reported in the figure legends refer to the number of pairs. Pyramidal neurons were identified by morphology and location. To ensure stable recording, membrane holding current, input resistance, and pipette series resistance were monitored throughout recording. All recordings were made at 20--25°C using glass patch electrodes filled with an internal solution consisting of 135 mM CsMeSO~4~, 8 mM NaCl, 10 mM HEPES, 0.3 mM EGTA, 4 mM Mg-ATP, 0.3 mM Na-GTP, 5 mM QX-314, and 0.1 mM spermine and an external solution containing 119 mM NaCl, 2.5 mM KCl, 4 mM MgSO~4~, 4 mM CaCl~2~, 1 mM NaH~2~PO~4~, 26.2 mM NaHCO~3~ and 11 mM glucose bubbled continuously with 95% O~2~ and 5% CO~2~. Recordings of IPSCs were made in the presence of D-APV (100 μM, Cayman Chemical, Ann Arbor, MI) and NBQX (10 μM, Abcam, UK) to block NMDA and AMPA-mediated currents respectively. Recordings of excitatory current were made in the presence of picrotoxin (100 μM, Spectrum Chemical, Gardena, CA) to block inhibitory currents and a small (50 nM) amount of NBQX to reduce epileptiform activity at −70 mV (AMPA). AMPAR-mediated currents were measured at the peak of the current.

Statistical analysis {#s4-8}
--------------------

All paired whole-cell data were analysed using a two-tailed Wilcoxon matched-pairs signed rank test. For comparisons between different experimental groups, a Mann Whitney test was used on the ratios of the transfected cell to the control cell. Data analysis was carried out in Igor Pro (Wavemetrics, Portland, OR), GraphPad Prism (GraphPad Software, La Jolla, CA) and Excel (Microsoft, Redmond, WA).
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Thank you for submitting your article \"Distinct roles for extracellular and intracellular domains in neuroligin function at inhibitory synapses\" for consideration by *eLife*. Your article has been favorably evaluated by Gary Westbrook (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors. The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Nguyen et al. report the roles of distinct extracellular and intracellular domains of neuroligins (NLGNs) at inhibitory synapses. The authors first find that NLGN2 but not NLGN3 is required for inhibitory synaptic transmission in cultured neurons. In follow-up experiments, the authors mainly use molecular replacement approaches to map out critical regions associated with NLGN2-dependent regulation of inhibitory transmission. The authors identify two domains in the extracellular region of NLGN2 (splice A site domain and an uncharacterized adjacent domain) that confer NLGN function at inhibitory synapses. Intracellularly, the authors find that a c-tail from NLGN1/2/3 is required for NLGN function at inhibitory synapses. Furthermore, they find that previously identified cytoplasmic domains including the PDZ-binding motif and gephyrin-binding domain are not required for NLGN2 function, but that an upstream region (δ 117-133) and two residues within this region, one autism-related (R705) and the other phosphorylatable (S714), are important for NLGN2 function. Interestingly, the authors find that these residues together with a residue in the gephyrin-binding domain (Y770) are collectively important for NLGN2 function; combinations of residues both in the gephyrin-dependent and -independent pathways are important to fully support NLGN2 function. This is an interesting, well-performed and thorough study, and a well-written manuscript that is appropriate for *eLife*. The findings provide novel insight into the relevance and function of previously unidentified regions of Nlgn at inhibitory synapses.

Essential revisions:

1\) This study used many constructs carrying deletions and mutations of NLGN2 and NLGN3. Ideally, their total and surface expression levels should be tested using biochemical (i.e. biotinylation) or cell biological methods, although some were tested by surface staining ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). The extracellular deletion variants were verified of their support for excitatory synaptic transmission ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), which is admittedly a nicer way, but most of the cytoplasmic variants of NLGN2 were not tested for total/surface expression.

2\) The authors identify the proximal part of the extracellular region of Nlgn2 as required for the functional differences between Nlgn2 and Nlgn3 ([Figure 3](#fig3){ref-type="fig"}). The study would be enhanced if the authors could identify the property that makes this proximal region unique. The authors could use binding assays to test if this proximal region confers binding properties to Nlgn3 that allow binding of this Nlgn3 to neurexins expressed at inhibitory synapses. They could also use similar binding assays to test whether this proximal region might be required to allow Nlgn3 to associate with Nlgn2 in heteromers at inhibitory synapses. Even if the results are negative it would still be informative, as this would strengthen their alternative hypothesis that there could be another molecule interacting with the Nlgn2 proximal domain (subsection "Extracellular region confers specificity").

3\) A challenge in dissecting the contribution of the Nlgn c-tail to inhibitory synaptic function is that the downstream signaling pathways are largely unknown. Although their experiments suggest that the R705C mutation acts via a gephyrin-dependent pathway, the molecular basis of this is less clear. The authors previously showed that in Nlgn4, this mutation impairs phosphorylation of neighboring T707 by PKC (Bemben et al., PNAS 2015). T707 is absent in Nlgn1-3, suggesting an alternative mechanism. Biochemical analysis of gephryin binding in R705C mutants would help to clarify how this mutation might affect the gephyrin-dependent pathway. In these experiments, the R705C mutant can be compared to S714A mutant, which would not be expected to affect gephyrin binding. In addition, is it possible to check that the phosphorylation of neighboring S714 is not affected by the R705C mutation?

4\) The authors propose that S714 modulates a gephyrin-independent pathway, based on their findings that the S714A single mutation does not impair inhibitory responses, whereas the S714A-Y770A double mutant does. The authors could functionally test the effect of the single S714A mutation by expressing the single Nlgn2-S714A mutant in an Nlgn1-3 miR+/gephyrin-miR+ background, which would be expected to fail to enhance inhibitory responses.

5\) The main approach employed in the current study is electrophysiological recordings of rat organotypic slice cultured neurons. To corroborate the key findings, some of the phenotypes (if not all) should be confirmed by independent immunocytochemical approaches.

10.7554/eLife.19236.023

Author response

*\[...\] Essential revisions:*

1\) This study used many constructs carrying deletions and mutations of NLGN2 and NLGN3. Ideally, their total and surface expression levels should be tested using biochemical (i.e. biotinylation) or cell biological methods, although some were tested by surface staining ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). The extracellular deletion variants were verified of their support for excitatory synaptic transmission ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), which is admittedly a nicer way, but most of the cytoplasmic variants of NLGN2 were not tested for total/surface expression.

We have done surface staining for the HA-tag construct in two of our most critical double point mutations which exhibited impaired inhibitory synaptic transmission ([Author response image 1](#fig9){ref-type="fig"}). As shown in [Author response image 1](#fig9){ref-type="fig"}, both the NLGN2-R705C-S714A and NLGN2-S714A-Y770A mutants did not display any impairment in surface trafficking. Actually, they seem to be expressed to a greater extent than wild-type NLGN2 on the surface.10.7554/eLife.19236.017Author response image 1.Dissociated hippocampal rat cultures were prepared at E18.5 and transfected with NLmiRs-GFP and either NLGN2, NLGN2-R705C-S714A, or NLGN2-S714A-Y770A at DIV 8.After 1 week cells were stained for surface HA (Abcam ab9110, 1:200). HA signal was normalized to GFP. (NLGN2 n=5 cells, NLGN2-R705C-S714A n=7 cells, NLGN2-S714A-Y770A n=7 cells; \*p=0.0177, \*\*p=0.0025).**DOI:** [http://dx.doi.org/10.7554/eLife.19236.017](10.7554/eLife.19236.017)

2\) The authors identify the proximal part of the extracellular region of Nlgn2 as required for the functional differences between Nlgn2 and Nlgn3 ([Figure 3](#fig3){ref-type="fig"}). The study would be enhanced if the authors could identify the property that makes this proximal region unique. The authors could use binding assays to test if this proximal region confers binding properties to Nlgn3 that allow binding of this Nlgn3 to neurexins expressed at inhibitory synapses. They could also use similar binding assays to test whether this proximal region might be required to allow Nlgn3 to associate with Nlgn2 in heteromers at inhibitory synapses. Even if the results are negative it would still be informative, as this would strengthen their alternative hypothesis that there could be another molecule interacting with the Nlgn2 proximal domain (subsection "Extracellular region confers specificity").

There are multiple hurdles underlying the suggested experiment to express different variants of neurexins to test binding of NLGN3. First, there is no readily available library of all the neurexin variants expressed at inhibitory synapses from which we can obtain constructs to overexpress. Even if there were, there are a plethora of neurexin variants and combinations, including splice isoforms, which could be possibly expressed, making it unwieldy to perform this experiment.

However, we have attempted to characterize our critical extracellular domain further by looking at the crystal structure of NLGN2 which has previously been resolved \[1\]. We aligned the structure of NLGN2 (3BL8) to the crystal structure of the NLGN1/Neurexin1β complex \[2\] (3BIW) ([Author response image 2](#fig10){ref-type="fig"}), to approximate the location at which neurexin would bind to NLGN2. Highlighted in red is our critical extracellular domain, which appears to be on the side of the neuroligin away from the neurexin-binding interface, suggesting that molecular partners other than neurexins underlie the ability of this domain to confer neuroligin function at inhibitory synapses. Indeed, there are a number of candidate molecules hypothesized to associate with NLGN2 \[3\] and it would be of interest for future studies to screen through possible interactors for binding to our identified domain. One caveat of this structural prediction is that the neurexin binding sites are based on the NLGN1/Neurexin1β complex and it is possible that neurexins at inhibitory synapses bind to NLGN2 at a different site. In addition, we noticed that the published crystal structure of NLGN2 is missing 14 amino acids around and within the splice site A site, which could affect the true structure of the protein.

We were unable to characterize and align NLGN3 to our structural analysis due to the lack of a crystal structure and the inability of structure prediction software to fully predict the structure of our protein due to the highly disordered region around splice site A.10.7554/eLife.19236.018Author response image 2.Crystal structure of NLGN2 dimer (in blue) aligned with Neurexin1β structure (in orange).In red is the critical extracellular domain in NLGN2 identified in our study.**DOI:** [http://dx.doi.org/10.7554/eLife.19236.018](10.7554/eLife.19236.018)

We do not think that our identified critical domain in the proximal region is required to allow NLGN3 to associate with NLGN2 in heteromers since wild-type NLGN3 already associates with NLGN2, as shown in the blot ([Author response image 3](#fig11){ref-type="fig"}). In this experiment, HEK cells were transfected with constructs for either GFP alone, GFP+NLGN2, GFP+NLGN3, or both NLGN2 and 3. The NLGN2 construct contained an HA tag that we immunoprecipitated for and then blotted for NLGN3 to determine if the two bind. We see robust NLGN3 signal in the IP samples from cells expressing both NLGN2 and NLGN3. We can also see that we did enrich for HA-associated protein complexes since the NLGN3 signal in the input lane from cells expressing GFP+ NLGN3 goes away in the IP lane. We see some signal in the GFP+NLGN2 samples in the IP lane and this is due to the fact that the antibody we use can also detect other neuroligins when they are highly overexpressed.10.7554/eLife.19236.019Author response image 3.HEK293T cells were transfected with either GFP, GFP+NLGN2, GFP+NLGN3, or NLGN2+NLGN3.After 2 days lysates were harvested and incubated in HA-conjugated agarose beads (Sigma-Aldrich, Saint Louis, MO) to immunoprecipitate HA-tagged protein complexes. Samples were run on a 4--12% Bis-Tris gel and probed for HA (Santa Cruz 1:2000), NLGN3 (Synaptic Systems 1:1000), and actin (Millipore C4 1:5000). Input samples are 3% of IP samples. Blots are representative of at least 2 experimental and technical replicates. Size indicated on left in kDa.**DOI:** [http://dx.doi.org/10.7554/eLife.19236.019](10.7554/eLife.19236.019)

*3) A challenge in dissecting the contribution of the Nlgn c-tail to inhibitory synaptic function is that the downstream signaling pathways are largely unknown. Although their experiments suggest that the R705C mutation acts via a gephyrin-dependent pathway, the molecular basis of this is less clear. The authors previously showed that in Nlgn4, this mutation impairs phosphorylation of neighboring T707 by PKC (Bemben et al., PNAS 2015). T707 is absent in Nlgn1-3, suggesting an alternative mechanism. Biochemical analysis of gephryin binding in R705C mutants would help to clarify how this mutation might affect the gephyrin-dependent pathway. In these experiments, the R705C mutant can be compared to S714A mutant, which would not be expected to affect gephyrin binding. In addition, is it possible to check that the phosphorylation of neighboring S714 is not affected by the R705C mutation?*

We transfected HEK cells with gephyrin and either NLGN2, NLGN2-R705C, or NLGN2-S714A. We then immunoprecipitated for the HA-tagged NLGN2 and blotted for gephyrin to see if we could detect any differences in gephyrin binding to the different point mutants. As shown ([Author response image 4](#fig12){ref-type="fig"}), we could not detect any noticeable difference in the gephyrin signal between the point mutants. This result is not definitive in showing that there is no effect on gephyrin interactions with our point mutants due to the fact that we are highly overexpressing them and thus it is possible that there are slight nuances in the interaction that we are not able to pick up in this assay. In addition, we are using non-neuronal cells which could impact our results. While it would be ideal to use neuronal cells for this assay, we would be hampered by the fact that the gephyrin-NLGN2 interaction itself is quite weak. As shown in our blots, we see robust gephyrin signal in our input lanes. However, when we enrich for NLGN2, we see about 90% less signal suggesting that most of the gephyrin being overexpressed is not binding to NLGN2. This signal would be even weaker/undetectable if we were to use neuronal cells and endogenous gephyrin.

Unfortunately, we are not able to check whether phosphorylation of neighboring S714 is affected by the R705C mutation due to lack of a phospho-specific antibody for S714.10.7554/eLife.19236.020Author response image 4.HEK293T cells were transfected with either GFP, NLGN2+gephyrin, NLGN2R705C+gephryin, or NLGN2S714A+gephyrin.After 2 days lysates were harvested and incubated in HA-conjugated agarose beads (Sigma) to immunoprecipitate HA-tagged protein complexes. Samples were run on a 4--12% Bis-Tris gel and probed for HA (Santa Cruz 1:2000), gephyrin (Synaptic Systems 1:5000), and actin (Millipore C4 1:5000). Input samples are 3% of IP samples. Blots are representative of at least 2 technical replicates. Size indicated on left in kDa.**DOI:** [http://dx.doi.org/10.7554/eLife.19236.020](10.7554/eLife.19236.020)

*4) The authors propose that S714 modulates a gephyrin-independent pathway, based on their findings that the S714A single mutation does not impair inhibitory responses, whereas the S714A-Y770A double mutant does. The authors could functionally test the effect of the single S714A mutation by expressing the single Nlgn2-S714A mutant in an Nlgn1-3 miR+/gephyrin-miR+ background, which would be expected to fail to enhance inhibitory responses.*

We thank the reviewer for this suggestion. We have performed this experiment and indeed expression of NLGN2-S714A along with NLGN1-3miR + Gephyrin-miR fails to enhance inhibitory responses.10.7554/eLife.19236.021Author response image 5.Scatterplot and bar graph showing expression of NLGN2S714A along with NLGN1-3miR and Gephyrin-miR fails to enhance inhibitory responses and is significantly different than expression of full-length NLGN2 on the NLGN1-3miR background (n = 8, \*\*p=0.0023, \*\*\*\*p\<0.0001).Scale bar represents 25pA and 50ms.**DOI:** [http://dx.doi.org/10.7554/eLife.19236.021](10.7554/eLife.19236.021)

*5) The main approach employed in the current study is electrophysiological recordings of rat organotypic slice cultured neurons. To corroborate the key findings, some of the phenotypes (if not all) should be confirmed by independent immunocytochemical approaches.*

With due respect, for multiple reasons we would argue that immunocytochemical approaches would not significantly enhance the impact of our study. First, previous work in our lab has shown that neurons expressing point mutants which affect the function of a NLGN, as determined by electrophysiological recordings, could display normal presynaptic specializations \[4\]. In addition, it is difficult to determine the effects our mutants have on postsynaptic specializations since there is no structural approximation of inhibitory synapse number equivalent to the spine density used for excitatory synapses. Indeed, the postsynaptic marker that is used most often for inhibitory synapses is gephyrin, which would not be ideal to use for our purposes.
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